Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.B Braun Medical has received the US Food and Drug Administration (FDA) approval for its application of 1g and 2g Ceftazidime (Cephalosporins) for Injection and Dextrose Injection in its DUPLEX drug delivery system.
Subscribe to our email newsletter
The drug delivery system is a two-compartment, flexible, eco-friendly IV container that stores pre-measured drug and diluent doses.
DUPLEX can be stored at room temperature and fits in automated medication dispensing systems.
DUPLEX helps healthcare facilities achieve surgical care improvement project (SCIP), the Joint Commission and USP 797 compliance that improve the practice of healthcare professionals while advancing patient safety.
B Braun Medical Pharmaceuticals & Drug Delivery Marketing vice president Rob Albert said by adding 1g and 2g Ceftazidime within the DUPLEX System meets customer demands for providing a broad spectrum of intravenous therapies.
"The DUPLEX System ensures sterility through a closed-system design with barcodes – which contribute to reduce medication errors," Albert said.